Slide 1: Results as of 03/31/26
CHEMETD) CHEMED CORPORATION Results as of 03/31/26
Slide 2: Safe Harbor and Regulation G Statement
Safe Harbor & Regulation G Statement Safe Harbor and Regulation G Statement This presentation contains information about Chemed’s EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude compo
Slide 3: Cumulative Results Since the VITAS Acquisition
Results Since Vitas Acquisition Cumulative Results Since the VITAS Acquisition For the years ended December 31, 2003, through 2025 (1) (2) (3) CAGR One Three Twenty-Two Year Year Year (a) Chemed (1) Service revenues and sales 4.1% 5.8% 10.9% (2) Adj. net income (11.3%) 1.5% 18.2% (3) Adj. diluted EP
Slide 4: Chemed – Purchase of Capital Stock
Purchase of Capital Stock Chemed – Purchase of Capital Stock For the Period January 1, 2007, through March 31, 2026 ($000) (1) (2) (3) (4) Total Free Shares Returned to Cash Flow Repurchased Dividends Shareholders Generated (1) (1) Activity in 2007 $ 127,881 $ 5,888 $ 133,769 $ 72,944 (2) Activity i
Slide 5: Adj. EPS and Stock Price History
Adj. EPS / Stock Price History (1) (2) Adj. EPS and Stock Price History Chemed has delivered strong and consistent EPS to stockholders since 2003, 19.9% 22-year CAGR Adj. Diluted EPS Adj. Stock Price (1) Adjusted Diluted EPS (non GAAP); see Appendix at the back of this presentation for reconciliatio
Slide 6: Chemed – Consolidated Summary of Operations
Consolidated Summary of Operations Chemed – Consolidated Summary of Operations For the years ended December 31, 2003, through 2025 (in thousands, except per share data) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Average Annual 2003 2011 2013 2015 2017 2019 2021 2022 2023 2024 2025 Inc./(Dec.
Slide 7: Chemed - Results from Continuing Operations
Results from Continuing Operations Chemed - Results from Continuing Operations (in thousands, except per share data) (1) (2) (3) (4) (5) (6) Full-Year Results Three Months Ended March 31, Fav/(Unfav) Fav/(Unfav) 2024 2025 % Growth 2025 2026 % Growth (1) Service Revenues and Sales $2,431,287 $2,529,9
Slide 8: Chemed Corporation Revenue
Results from Continuing Operations Chemed Corporation Revenue 2024 2025 VITAS VITAS Roto-Rooter Roto-Rooter Chemed Chemed Adjusted EBITDA (a) Chemed Central Support Adjusted EBITDA (a) Chemed Central Support VITAS VITAS COS COS Roto-Rooter VITAS VITAS Roto-Rooter Central Central Support Roto-Rooter
Slide 9: Roto-Rooter Company Overview
ROTO- ( ROOTER. Company Overview PLUMBING & WATER CLEANUP
Slide 10: Company Overview
Company Overview Company Overview ● Largest provider of plumbing and drain cleaning services in North America ● Provides plumbing services to approximately 90% of the United States and 30% of the Canadian population ● Provides plumbing and drain cleaning services in 122 company-owned territories and
Slide 11: Chemed Growth Strategy – Roto-Rooter
Chemed - Growth Strategy Chemed Growth Strategy – Roto-Rooter ● Continue to increase efficiency ● Acquire franchisee territories at reasonable valuations ● $75 - $100 million in franchise street sales in desirable markets ● Purchase at 6-8 times Proforma Adjusted EBITDA ● Minimal capital expenditure
Slide 12: Roto-Rooter – Gross Revenue Analysis ($000)
Gross Revenue Analysis Roto-Rooter – Gross Revenue Analysis ($000) $368.2 $392.1 $427.8 $453.6 $518.5 $592.0 $663.6 $750.7 $882.5 $938.0 $957.1 $909.5 $911.7 (a) 2018 - 2025 reflect GAAP Revenue Recognition Accounting Standard. Prior years are not restated for the 2018 Revenue Recognition Accounting
Slide 13: Roto-Rooter – Summary of Operations
Summary of Operations Roto-Rooter – Summary of Operations 2004 through 2011 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) 2004 2005 2006 2007 2008 2009 2010 2011 (1) Service Revenues $ 276,611 $ 297,337 $ 319,495 $ 344,632 $ 340,496 $ 335,893 $ 354,735 $ 369,698 and Sales (a) (2
Slide 14: Roto-Rooter – Summary of Operations
Summary of Operations Roto-Rooter – Summary of Operations 2013 through 2025 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) Average Annual Inc./(Dec.) 2013 2015 2017 2019 2021 2022 2023 2024 2025 2004-2025 (1) Service Revenues $ 368,216 $ 427,837 $ 518,464 $ 657,371 $ 878
Slide 15: Results from Continuing Operations
Results from Continuing Operations Results from Continuing Operations ($000) (1) (2) (3) (4) (5) (6) Full-Year Results Three Months Ended March 31, Fav/(Unfav) Fav/(Unfav) 2024 2025 % Growth 2025 2026 % Growth (1) Service Revenues and Sales $ 900,309 $ 899,877 (0.0%) $ 239,543 $ 237,495 (0.9%) (2) N
Slide 16: Future of Roto-Rooter
Future of Roto-Rooter Future of Roto-Rooter ⚫ Continue to Consolidate Franchises ● Purchase at reasonable multiples ● Avoid over-paying for current acquisitions ● Inflates expectations/demands of remaining franchisees ⚫ Utilize Cash Flow for: ● Purchase of franchises ● Acquisition of hospices ● Shar
Slide 17: VITAS Company Overview
Heaitione 4 \ V TA S Company Overview Healthcare
Slide 18: Company Overview
Company Overview Company Overview ⚫ One of the largest providers of hospice services for patients with severe, life-limiting illnesses with approximately 7-8% of the U.S. market share ⚫ Operates a comprehensive range of hospice services through 59 operating programs in 15 states and the District of
Slide 19: Analysis of Revenue
Analysis of Revenue Days of Care – 2025 Revenues - 2025 Routine Home Care General Inpatient Continuous Home Care Revenue and Expenses - 2025 Adjusted EBITDA - 2025 19 VITAS Healthcare
Slide 20: Operations – Percent of Revenue
Operations – Percent of Revenue Operations as a Percent of Revenue (1) 2018 - 2025 include the impact of the new revenue recognition accounting standard. Prior periods are not restated for the 2018 revenue recognition accounting standard. 20 VITAS Healthcare
Slide 21: Locations
Locations Philadelphia Chicagoland Columbus Kansas City Central St. Louis LaSalle Pittsburgh Dayton Fairview Chicagoland Chicagoland Milwaukee Heights Northwest South Cincinnati Connecticut Metro Greater Sacramento Valley & Foothills New Jersey North New Jersey Shore New Jersey West East Bay Delawar
Slide 22: Florida Locations
Florida Locations Tallahassee Jacksonville Pensacola Panama City Nature Coast Marion Volusia - Flagler Citrus Lake/Sumter Pasco Central Florida Mid-State Florida Brevard Pinellas Treasure Coast Southwest Florida Palm Beach Collier Broward Miami-Dade/Monroe 22 22
Slide 23: 2025 Discharge Rate - Total
2025 Discharge Rate - Total VITAS 2025 Discharge Rate – Total Median 23 VITAS Healthcare
Slide 24: 2025 Discharge Rate - Total After 180 Days
2025 Discharge Rate - Total VITAS 2025 Discharge Rate – Total After 180 Days 24 VITAS Healthcare
Slide 25: Admission by Diagnosis - 2025
Admission by Diagnosis - 2025 VITAS Admission by Diagnosis - 2025 25 VITAS Healthcare
Slide 26: Discharge Rate – All Diagnosis
Discharge Rate – All Diagnosis VITAS 2025 Discharge Rate – All Diagnosis Population: 70,530 100% 90% 80% Cancer 26.1% of Total (MLOS 11) 70% Cardio 14.7% of Total (MLOS 24) Cerebro 27.7% of Total (MLOS 52) 60% 100% Gastro 00.2% of Total (MLOS 4) 100% HIV 00.1% of Total (MLOS 7) 50% Ill Def 00.0% of
Slide 27: Discharge Analysis 2004 - 2025
Discharge Analysis 2004 - 2025 Analysis of VITAS Discharges 2004-2025 Total Discharges Total Live Discharges 27 VITAS Healthcare
Slide 28: Gross Revenue By Level of Care
Gross Revenue by Level of Care 2003-2025 VITAS Analysis of Gross Revenue By Level of Care 2003 through 2025 ($000) 28 VITAS Healthcare
Slide 29: Analysis of Average Daily Census (ADC)
Daily Census Average 2003 - 2025 VITAS Analysis of Average Daily Census (ADC) 2003 through 2025 20,000 17,742 18,846 19,042 18,613 18,003 16,550 15,992 17,325 18,000 15,385 14,383 16,000 13,406 14,000 11,980 11,477 10,030 12,000 10,000 7,428 8,000 6,000 4,000 2,000 - 2003 2005 2007 2009 2011 2013 20
Slide 30: Direct Gross Profit Contribution Margin By Level of Care
Direct Gross Profit Contribution VITAS Analysis of Direct Gross Profit Contribution Margin By Level of Care 2003 through 2025 (in millions) 30 VITAS Healthcare
Slide 31: VITAS – Summary of Operations
Summary of Operations VITAS – Summary of Operations For The Years Ended December 31, 2004 through 2011 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) 2004 2005 2006 2007 2008 2009 2010 2011 (1) Service Revenues and Sales $ 531,136 $ 618,613 $ 699,092 $ 755,426 $ 808,445 $ 854,343
Slide 32: VITAS – Summary of Operations
Summary of Operations VITAS – Summary of Operations For The Years Ended December 31, 2013 through 2025 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) Average Annual Inc./(Dec.) 2013 2015 2017 2019 2021 2022 2023 2024 2025 2004-2025 (1) Service Revenues and Sales $ 1,045,
Slide 33: VITAS – Operating Results
Operating Results VITAS – Operating Results (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) Average Annual 2003 (b) 2004 (b) 2006 2008 2010 2012 2014 2016 2018 2019 2021 2022 2023 2024 2025 Inc./(Dec.) (1) Net Service Revenue $ 441,017 $ 531,
Slide 34: VITAS – Results from Continuing Operations
Operating Results VITAS – Results from Continuing Operations ($000) (1) (2) (3) (4) (5) (6) Full-Year Results Three Months Ended March 31, Fav/(Unfav) Fav/(Unfav) 2024 2025 % Growth 2025 2026 % Growth (1) Service Revenues Before Medicare Cap $ 1,539,392 $ 1,657,262 7.7% $ 409,725 $ 422,393 3.1% (2)
Slide 35: Future of VITAS
Future of VITAS Future of VITAS Short-term ● Continue organic growth ● Acquisitions ● Fragmented industry ● Dominated by “Mom & Pop” not-for-profits ● Bottom 50% of provider numbers have an estimated average operating margin in hospice of 4% - 8%* ● Access to reasonably priced capital critical to ex
Slide 36: VITAS – Operating Metrics
Operating Metrics VITAS – Operating Metrics ($000) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) 2021 2022 2023 2024 2025 2026 Operating Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 (1) Average Daily Census (ADC) 18,050 17,9
Slide 37: Appendix
CHEMETD) CHEMED CORPORATION
Slide 38: EPS and Stock Price History
EPS & Stock Price History EPS and Stock Price History Chemed has delivered strong and consistent EPS to stockholders since 2003, 17.2% 22-year CAGR Diluted EPS Adj. Stock (GAAP) Price (1) Diluted EPS from continuing operations (GAAP) 38 (2) Adjusted for stock splits Chemed Corporation
Slide 39: Medicare Hospice Spending (in billions)
Medicare Hospice Spending Medicare Hospice Spending (in billions) $23.7 $25.7 $23.1 $22.4 $20.9 $19.2 $17.9 $16.8 $15.9 $15.1 $15.1 $15.1 $13.8 $12.9 $12.0 8% 7% 9% 0% 0% 5% 6% 7% 7% 9% 7% 8% $2.4 9.9% Compounded annual growth rate from 1999 to 2023 Sources: MedPAC Report to the Congress – 2011 - 20
Slide 40: Growth in Hospice Programs
Growth in Hospice Programs Growth in Hospice Programs Source: MedPAC Report to the Congress – 2011 through 2025 40 Appendix
Slide 41: Reconciliation of Adj. EBITDA - Chemed
Reconciliation of Adj. EBITDA - Chemed CHEMED CORPORATION RECONCILIATION OF ADJUSTED EBITDA FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2025 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (9) (10) 2004 2011 2013 2015 2017 2019 2021 2022 2023 2024 2025 Reconciliation of Adjusted EBITDA (1) Net
Slide 42: Reconciliation of Adj. Net Income - Chemed
Reconciliation of Adj. Net Income - Chemed CHEMED CORPORATION RECONCILIATION OF ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2025 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 2004 2011 2013 2015 2017 2019 2021 2022 2023 2024 2025 Reconciliation of Adjusted Net In
Slide 43: Reconciliation of Adj. EBITDA and Adj. Net Income – Roto-Rooter
Reconciliation of Adj. EBITDA and Adj. Net Income– Roto-Rooter ROTO-ROOTER GROUP RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2025 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 2004 2005 2006 2007
Slide 44: Reconciliation of Adj. EBITDA and Adj. Net Income - VITAS
Reconciliation of Adj. EBITDA And Adj. Net Income - VITAS VITAS HEALTHCARE GROUP RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2025 (a) (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) 2004 2005 2006
Slide 45: Reconciliation of Adj. EBITDA and Adj. Net Income - Chemed
Reconciliation of Adj. EBITDA and Adj. Net Income - Chemed RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED NET INCOME FOR THE FIRST THREE MONTHS OF 2025 AND 2026 (IN THOUSANDS) 2025 2026 Reconciliation of Adjusted EBITDA (1) Net income $ 71,757 $ 66,302 (2) Interest expense 329 512 (3) Income taxes 2
Slide 46: Reconciliation of Adj. EBITDA – Roto-Rooter
Reconciliation of Adj. EBITDA – Roto-Rooter ROTO-ROOTER GROUP RECONCILIATION OF ADJUSTED EBIT AND ADJUSTED EBITDA FOR THE FIRST THREE MONTHS OF 2025 AND 2026 (IN THOUSANDS) 2025 2026 Reconciliation of Adjusted EBIT and EBITDA (1) Net income $ 39,944 $ 35,784 (2) Interest expense 132 136 (3) Income t
Slide 47: Reconciliation of Adj. EBITDA – VITAS
Reconciliation of Adj. EBITDA – VITAS VITAS HEALTHCARE GROUP RECONCILIATION OF ADJUSTED EBITDA FOR THE FIRST THREE MONTHS OF 2025 AND 2026 (IN THOUSANDS) Reconciliation of Adjusted EBITDA 2025 2026 (1) Net income $ 50,030 $ 52,207 (2) Interest expense 48 50 (3) Income taxes 18,035 16,528 (4) Depreci
Slide 48: 255 East 5th Street Suite 2600 Cincinnati, OH 45202
255 East 5th Street Kevin J. McNamara Suite 2600 President and CEO kevin.mcnamara@chemed.com Cincinnati, OH 45202 Michael D. Witzeman EVP, CFO and Controller (513) 762-6690 Phone michael.witzeman@chemed.com (513) 762-6919 Fax www.chemed.com Rev. 02/2025 Chemed Corporation